Develops therapies to treat heart diseases associated with inflammation and fibrosis.
Cardiol Therapeutics Inc. is a clinical-stage life sciences company based in Oakville, Canada, dedicated to advancing therapies for cardiovascular disease (CVD) through innovative anti-fibrotic and anti-inflammatory treatments. At the forefront of its research is CardiolRx, the company's leading product currently undergoing Phase II/III multi-national trials. These studies are pivotal in assessing CardiolRx's efficacy and safety as a cardioprotective therapy aimed at reducing cardiovascular and respiratory events in hospitalized COVID-19 patients, as well as its potential in treating acute myocarditis.
In addition to its ongoing clinical trials, Cardiol Therapeutics is actively developing a subcutaneous formulation of CardiolRx. This formulation is specifically tailored to target fibrosis and inflammation in the heart, conditions intricately linked to the progression and development of heart failure. By focusing on these critical areas of cardiovascular health, the company aims to adress significant unmet medical needs and improve patient outcomes.
Founded in 2017, Cardiol Therapeutics has quickly positioned itself as a leader in the field of cardiovascular therapeutics. The company's headquarters in Oakville serve as a hub for its research and development efforts, bolstered by a commitment to rigorous scientific inquiry and strategic partnerships aimed at advancing novel treatments that hold promise for patients worldwide.